### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average	burden				
nours per response	e 0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)												
1. Name and Address of Reporting Person – Cunningham Ann Michelle  (Last) (First) (Middle) CO/VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE  (Street)			2. Issuer Name and Ticker or Trading Symbol VistaGen Therapeutics, Inc. [VTGN]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X_ Director 10% Owner						
			DIG 242	3. Date of Earliest Transaction (Month/Day/Year) 01/10/2019				_^					)	
			4. If Amendment, Date Original Filed(Month/Day/Year)					_X_	6. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person  Form filed by More than One Reporting Person				ie)	
SOUTH S	SAN FRAN	NCISCO, CA 94	080							Form filed by	More than One	Reporting Person		
(City	y)	(State)	(Zip)		T	able I -	Non-Deriva	tive Securities	Acquired	l, Disposed	of, or Ben	eficially Own	ed	
1.Title of S (Instr. 3)	ecurity			2A. Deen Execution any (Month/E	n Date, if	Code (Instr. 8	(A) (In	Securities Acquiring or Disposed of astr. 3, 4 and 5)  (A) or nount (D)	of (D) Ow Tra	Owned Following Reported Transaction(s)  (Instr. 3 and 4)  Owned Form Form Direct or Indi (I)			Ownership orm: Briect (D) Cr Indirect (I	Seneficial Ownership
Reminder:								ed in this for splays a curr					e	
		In an	. (	(e.g., puts,	calls, wa	rrants,	form dis nired, Dispos options, con	splays a curre sed of, or Bene evertible secur	ently vali eficially O ities)	d OMB co	ontrol nun	nber.		la v
1. Title of Derivative Security	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transact	tion of Deri's Secu Acqu (A) (Disp (D) (Inst	vative critics corrected or cosed of cr. 3, 4,	form dis	sed of, or Beneavertible secure ercisable and Date	ently vali	d OMB co	8. Price of		To. Ownershi Form of Derivative Security: Direct (Dor Indirect	(Instr. 4)
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if	4. Transact	5. Notion of Derice Secured (A) of Disp (D)	varive prices are described by the control of the c	form district, Disposoptions, con 6. Date Exe Expiration I (Month/Day  Date Exercisable	sed of, or Bencivertible secur evertible secur evertible and Date y/Year)	eficially Orities)  7. Title an Amount of Underlyin Securities	d OMB co	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownershi Form of Derivative Security: Direct (D) or Indirect	of Indire Benefici Ownersh (Instr. 4)

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Cunningham Ann Michelle CO/VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO, CA 94080	X				

## **Signatures**

/s/ Jerrold D. Dotson, Attorney-in-Fact	01/14/2019
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option reported herein will vest ratably, on a monthly basis, beginning on the date of issuance until March 31, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.